Neuropsychiatric Questionnaires in Systemic Lupus Erythematosus by Tani, C et al.
S-59
1Department of Clinical and Experimental 
Medicine, University of Pisa, Pisa, Italy;
2Department of Clinical and Experimental 
Medicine, Psichiatric Unit II, University 
of Pisa, Pisa, Italy; 
3Autoimmune Diseases Unit, Hospital 
Curry Cabral, CHLC, Lisbon, Portugal; 
4GenOMeC PhD, University of Siena, 
Siena, Italy. 
Chiara Tani, MD, PhD 
Laura Palagini, MD, PhD
Maria Francisca Moraes-Fontes, 
          MBBCh, PhD, FRCP (UK)
Linda Carli, MD
Mauro Mauri, MD
Stefano Bombardieri, MD, PhD 
Marta Mosca, MD, PhD
Please address correspondence to:
Chiara Tani, MD, PhD, 
Department of Clinical 
and Experimental Medicine
University of Pisa, 
Via Roma 67, 
56100 Pisa, Italy.
E-mail: chiaratani78@gmail.com
Received on September 1, 2014; accepted 
in revised form on September 10, 2014.
Clin Exp Rheumatol 2014; 32 (Suppl. 85): 
S59-S64.
© Copyright CliniCal and 
ExpErimEntal rhEumatology 2014.
Key words: systemic lupus 
erythematosus, questionnaire
Competing interests: none declared.
ABSTRACT
Patients with systemic lupus erythema-
tosus (SLE) can be affected by a mul-
titude of neurologic and psychiatric 
symptoms with a wide range of preva-
lence and severity. Irrespectively from 
attribution to SLE or other causes, neu-
ropsychiatric (NP) symptoms strongly 
impact short-term and long-term out-
comes, thus NP evaluation during rou-
tine clinical practice in SLE should be 
undertaken regularly.  
The assessment of NP involvement in 
SLE patients is challenging and the 
available diagnostic tools fail to guar-
antee optimal diagnostic accuracy, sen-
sitivity to changes as well as feasibility 
in routine clinical care.
Standardised questionnaires (both phy-
sician-administered and self-reported) 
can offer valuable help to the treating 
physician to capture all possible NP 
syndromes; few SLE-specific NP ques-
tionnaire have been developed but vali-
dation in large cohort or cross-cultural 
adaptations are still pending. On the 
other hand, general instruments have 
been largely applied to SLE patients. 
Both kinds of questionnaires can ad-
dress all possible NP manifestations 
either globally or, more frequently, fo-
cus on specific NP symptoms. These 
latter have been mainly used in SLE 
to detect and classify mild and subtle 
symptoms, more likely to be overlooked 
during routine clinical assessment such 
as headache, cognitive impairment and 
psychiatric manifestations.
In conclusion, this literature review 
highlights a clear case for validation 
studies in this area and the wider imple-
mentation of questionnaires to assess 
NP involvement is still warranted. The 
broader use of such instruments could 
have important consequences; first of 
all, by standardising symptom assess-
ment, a better definition of the preva-
lence of NP manifestation across differ-
ent centres could be achieved. Second-
ly, prospective studies could allow for 
the evaluation of clinical significance 
of mild symptoms and their impact on 
the patient’s function and quality of life.
Introduction
Patients with systemic lupus erythema-
tosus (SLE) may present a wide spec-
trum of neurological and psychiatric 
symptoms of a variable degree of sever-
ity. Despite some advances in under-
standing the general disease pathogen-
esis, neuropsychiatric SLE (NPSLE) 
remains a clinical challenge for the 
treating physician, both from a diagnos-
tic and a therapeutic perspective (1-4).
NP manifestations in SLE range from 
common clinical symptoms such as 
headache, mood disorders, and cogni-
tive complaints, to less frequent mani-
festations such as psychosis, myelopa-
thy, and peripheral neuropathies. There 
is considerable uncertainty surrounding 
several issues, including the true  preva-
lence of neuropsychiatric (NP) events, 
their attribution to SLE or to other caus-
es, and their clinical significance. 
In this review we summarise the avail-
able evidence concerning the assess-
ment of neuropsychiatric symptoms in 
SLE patients, with a special focus on 
tools for routine clinical care and long-
term observational studies.
Why do we need to assess 
neuropsychiatric symptoms in 
SLE patients?
Neuropsychiatric assessment during 
routine clinical practice in SLE should 
be undertaken regularly. Its importance 
is highlighted in the following frame-
work.
First of all, NP symptoms are common 
in SLE; estimates of prevalence have 
ranged from 14% to more than 90%, de-
pending on case definitions and patient 
selection (1-3). However, only a minor-
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ity of NP events in SLE is attributed 
to the disease itself (from 17 to 30% 
and, approximately depending upon the 
stringency of the attribution rules). No 
significant differences in impact on pa-
tient status between NP events attribut-
ed to SLE or not attributed to SLE have 
been reported, emphasising the im-
portance of including all NP events in 
clinical studies of NPSLE. Moreover, 
the presence of NP symptoms is associ-
ated with a poor prognosis, damage ac-
crual, reduced quality of life, and work 
disability. The presence of NP events, 
regardless of their attribution to SLE or 
to non-SLE causes, is associated with 
a significant negative effect on health-
related quality of life (4-5).
Literature data on mortality are some-
what contrasting but recent studies have 
shown an increased mortality rate com-
pared to the general population and to 
SLE patients without NP involvement 
(6-8). 
Secondly, NP symptoms may be pre-
sent early after disease onset in up to 
40% of the patients; in inception cohort 
studies, patients continue to accrue new 
NP events over time, attributed to both 
SLE and non-SLE causes. Nonetheless, 
the highest proportion of NP events at-
tributed to SLE occurs early during the 
disease course, and it could be hypoth-
esised that a therapeutic intervention 
at this time might be associated with 
a better prognosis. In this context, a 
therapeutic window of opportunity for 
immunosuppressive therapies has been 
suggested, further underscoring the 
need for NP assessment in routine SLE 
care (9, 10).
Assessment tools for 
neuropsychiatric manifestations
in SLE
The wide range of possible NP mani-
festations, as well as the lack of accu-
rate diagnostic biomarkers render the 
assessment of NP involvement in SLE 
a continuous challenge (11).
The availability of standardised ques-
tionnaires provides significant value 
as a practical tool to collect informa-
tion from individuals in a cost-effec-
tive manner; in addition to providing 
a cost-effective research tool for use 
in data collection, patient self-report 
questionnaires present invaluable in-
formation for the attending physician 
in routine clinical care. The availability 
of a validated questionnaire may help 
the patient prepare for the encounter 
with the doctor, and help the physician 
significantly in formulating clinical de-
cisions, while the patient does most of 
the work (12-14).
To date, few questionnaires have been 
specifically developed to assess NP 
involvement in SLE but several non 
SLE-specific tools that have been also 
tested in SLE patients. They address all 
possible NP manifestations either glob-
ally or, more frequently, focus on spe-
cific NP symptoms.
The first type of questionnaire has the 
advantage of providing a comprehen-
sive evaluation of the patient in a short 
timeframe, thus allowing for triage of 
potential candidates for further and more 
faithful assessments. On the other hand, 
questionnaires focusing uniquely on sin-
gle NP symptoms can reflect diagnostic/
classification accuracy but are time con-
suming and only applicable to selected 
cases in routine clinical practice.
“Global” NP questionnaires
In 2003, Denburg et al. developed a 
42- item self-administered neuropsy-
chiatric questionnaire including a range 
of NP-related symptoms and excluding 
major NP events. The NP-Q symptoms 
were divided into 26 neurologic, 13 
psychiatric, and 6 cognitive items.  The 
intent was to collect reasonably exhaus-
tive information systematically and 
rapidly, and in order to possibly alert 
the physician about the need for further 
investigations, but not as a replacement 
for diagnostic purposes. They applied 
the questionnaire to 76 patients with-
out overt NP syndromes, and found a 
significant association between higher 
item endorsement and lower cognitive 
function as well as significantly poorer 
cognitive performance in the high com-
pared to low endorser groups. These 
findings suggested that even “minor” 
NP symptoms might raise the suspicion 
of subclinical NP involvement in the 
absence of clinically evident NPSLE 
(15).
In 2010, with the same screening ob-
jective, Mosca et al. developed a phy-
sician-administered questionnaire to 
screen patients with SLE for the pres-
ence of symptoms suggestive of NP 
involvement in clinical practice, based 
on the ACR case definitions for NP 
syndromes in SLE. The questionnaire 
is composed of 27 weighted questions 
covering central nervous system (CNS) 
and psychiatric (Psyc) items, and was 
developed on the basis of a literature 
search and expert opinion consensus. 
In total, 139 SLE patients from 11 dif-
ferent European Centres were tested 
including 58 patients with recognised 
NPSLE and 81 patients without a histo-
ry of NPSLE. ROC analysis showed the 
best discriminating cut-off point corre-
sponded to a score of 17; this cut-off 
value offers a high sensitivity but a low 
specificity, in accordance with the aim 
of the questionnaire, namely for use as 
a first-level screening procedure. For 
the same reason, when CNS and Psych 
items were considered separately, the 
cut-off values identified to define posi-
tive patients were found to be 9 and 10, 
respectively. This questionnaire has the 
advantage of being simple to admin-
ister, complete in its cover of a wide 
range of manifestations and acceptable 
by physicians and patients because it 
minimises time and effort in compari-
son with previous forms of evaluation 
(16). Indeed, 5 to 10 minutes are re-
quired to be administered by a physi-
cian without specific training (personal, 
unpublished data). The questionnaire is 
regularly in use at the authors’ centres, 
being administered to all SLE outpa-
tients before the formal visit. External 
validations are currently ongoing.
The Adult Psychiatric Morbidity Ques-
tionnaire (APMQ), is a Brazilian screen-
ing instrument designed by Santana et 
al. to identify psychiatric morbidity in 
the general population. The validity and 
reliability of the QMPA have been es-
tablished in several community-based 
studies providing at a cutoff point of 7, 
a sensitivity of 83% and a specificity of 
71% (17).
In 2013, Beltrao et al. used the APMQ 
in the evaluation of psychiatric symp-
toms in a sample of 72 SLE patients, 
finding a higher frequency of abnormal 
APMQ (89%) mainly due to common 
mental disorders such as anxiety, so-
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matisation, irritability, depression (60 
patients, 93.7%), while only 4 patients 
were classified (6.3%) as having psy-
chosis (18).
With different purposes, The Mini In-
ternational Neuropsychiatric Interview 
(M.I.N.I. 6.0) is a short structured di-
agnostic interview for psychiatric dis-
orders. With an administration time of 
approximately 15 minutes, the M.I.N.I. 
6.0 is the structured psychiatric inter-
view of choice for psychiatric evalu-
ation and outcome tracking in clinical 
trials and epidemiological studies (19). 
In SLE this instrument was used by 
Jarpa et al. who applied the interview 
to 83 consecutive non-selected Chil-
ean patients with SLE, finding a 44.6% 
prevalence of psychiatric diagnoses, 
the most frequent of which was a major 
depressive episode which occurred in 
21.7% (20).
“Symptoms-specific” questionnaires
Disease-specific questionnaires have 
not been developed to assess single 
NP symptoms in SLE patients, but in-
struments developed and validated in 
general setting or other diseases have 
been widely applied in SLE. Among 
the several possible NP symptoms in 
SLE, questionnaires have been mainly 
used to detect and classify mild and 
subtle symptoms, more likely to be 
overlooked during routine clinical as-
sessment. 
Headache
Headache is a frequent complaint in 
SLE patients, being reported in up to 
72% of the patients; however, because 
it is not present more frequently in SLE 
patients than in the general population, 
its association with the underlying dis-
ease is still controversial (21-24).
Indeed, the term “lupus headache” im-
plies a unique form of headache that is 
rare (1.5%) and directly attributable to 
SLE. It represents a stand-alone item 
with similar definitions in the SLEDAI-
2K score (which defines lupus head-
ache as a severe, persistent headache 
that may be migrainous, but must be 
non-responsive to narcotic analgesia) 
and the British Isles Lupus Assessment 
Group (BILAG) 2004 index, (which 
defines lupus headache as a disabling 
headache that is unresponsive to narcot-
ic analgesia and lasts ≥3 days) (25, 26).
Headache is included in the ACR case 
definitions criteria and it is defined ac-
cording to the International Headache 
Society (IHS) classification in 5 subsets 
(migraine with and without aura, ten-
sion headache, cluster headache, head-
ache from intracranial hypertension, 
and intractable non-specific headache) 
(2, 27).
In 2001, 414 SLE patients were evalu-
ated for headache with the University 
of California, San Diego (UCSD) Mi-
graine Questionnaire, based on the IHS 
criteria to classify headache syndromes; 
headaches were reported in 62% of pa-
tients and 39% met diagnostic criteria 
for migraine (28, 29).
Recently, Tjensvoll et al. administered 
the Headache Impact Test-6 (HIT-6) 
and the Migraine Disability Assessment 
(MIDAS) questionnaires to evaluate 
headache-related disability in a sample 
of 77 SLE patients in comparison with 
healthy subject and patients suffering 
from Sjögren’s syndrome. The authors 
reported that patients have more severe 
headaches than healthy subjects a higher 
disability burden from headaches (30).
Cognitive impairment
Cognitive impairment (CI) is one of the 
more common NP symptoms in SLE, 
reported in up to 80% of the cases. 
Symptoms include cognitive slowing, 
decreased attention, impaired memory, 
and decision-making impairment (e.g. 
difficulty with multitasking, organisa-
tion, and planning). 
The frequent subtle and subclinical 
nature of CI as well as its intermittent 
and unpredictable expression, often 
occurring irrespectively of global SLE 
disease activity, marks the assessment 
of these symptoms as a diagnostic chal-
lenge (31-36).
So far, several CI instruments have 
been applied to SLE patients and their 
characteristics are reported in Table I.
The comprehensive 4-hour neuropsy-
chological battery administered by an 
expert neuropsychologist represents the 
gold standard for objective CI assess-
ment. In 1999, the ACR Committee for 
nomenclature and case definitions in 
NPSLE suggested a 1-hour test battery 
with demonstrated acceptable agree-
ment (90%) with formal neuropsycho-
logical tests and adequate reliability, 
suggesting its potential usefulness to 
identify SLE patients with CI (37).
To save time and standardise the pro-
cedure for non-expert administration, 
computer-based and audiotape-based 
instruments have also been tested in 
SLE (ANAM, PASAT) with good di-
agnostic accuracy. For instance, the 
ANAM battery takes 30–45 min to ad-
minister and includes a variety of tasks 
designed to assess neurocognitive ef-
ficiency through measures of response 
time and accuracy (38).
The Cognitive Symptom Inventory 
(CSI) score was proposed in 2002 in or-
der to overcome the limits of time and 
resources consumed by current objec-
tive evaluations of CI. This consisted of 
a rapid screening questionnaire consist-
ing of a 21-item self-report measure of 
cognitive function, with the objective 
of screening patients necessitating for-
mal CI assessment (39). However, in a 
validation study by Hanly et al. in 2012, 
no significant association between CSI 
scores and objective performance on a 
computer-administered neuropsycho-
logical test battery (ANAM) were ob-
served; instead, cognitive complaints of 
patients with SLE were associated with 
self-reported symptoms of anxiety and 
depression (40).
Anxiety and depression
Psychiatric manifestations are fairly 
common in SLE patients, occurring 
in up to 75% of cases. Among these, 
depression and anxiety are among 
the most frequent disorders observed. 
Studies cite a broad range of preva-
lence rates of depression ranging from 
17 to 75%, a much higher frequency 
than in the general population (18, 
20, 41). According to the Diagnos-
tic and Statistical Manual of Mental 
Disorders-DSM-5 edition, mood and 
anxiety disorders should be diagnosed 
using the Structured Clinical Interview 
for DSM Disorders (SCID) 2014 (42). 
These disorders can also be evalu-
ated by depression, anxiety and/or 
stress and personality scales. There is 
no agreement concerning an optimal 
method to evaluate psychiatric symp-
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toms in SLE. Indeed, differences in as-
sessment techniques appear to be the 
main explanation for the variability in 
findings and important methodological 
limitations are present in the available 
literature, preventing accurate descrip-
tions of the prevalence of depression 
and anxiety disorders in SLE. Moreo-
ver, it should be taken into account 
that the validity of the data reported by 
patients may not necessarily be gen-
eralised to all contests. This limit has 
been well described in rheumatoid ar-
thritis (RA) when evaluating patients 
for depression and other psychologi-
cal tendencies with questionnaires 
developed in the general population; 
indeed, in RA patients, the presence of 
somatic symptoms can be responsible 
of false positive answers to questions 
that in the general population can sug-
gest psychological complains. This as-
pect, named “criterion contamination” 
should be considered  when applying 
general instruments to specific patients 
groups (43, 44).
A summary of the studies and relevant 
instruments used in the evaluation of 
depression in SLE have been recently 
reviewed by our group (45). The Beck 
Depression Inventory (BDI) is one of 
the most widely used instruments for 
measuring the severity of depression 
in the general population and in SLE 
patients. BDI is a 21-question inven-
tory for self-assessment of depressive 
symptoms present in the month prior to 
evaluation. According to the BDI au-
thors’ recommendations, a BDI score 
greater than 10 is indicative of depres-
sive symptoms, while clinically sig-
nificant depression is defined when the 
BDI score is higher than 10 (46).
Recently, van Exel et al. used the BDI 
questionnaire to estimate the prevalence 
of depression in 102 SLE patients; they 
found a higher BDI score in SLE sub-
jects, corresponding to a depression 
prevalence of 16.6% versus 6.7% in 
the general population. Interestingly 
only 7% of SLE subjects with high BDI 
scores used antidepressants, suggesting 
inadequate recognition and treatment of 
depression in SLE (47).
The Self-rating Anxiety Scale (SAS) 
is one of the most widely used instru-
ments for measuring anxiety; it is a 20-
item self-report assessment scale and 
each question is scored on a Likert-type 
scale of 1–4. The presence of clinically 
relevant anxiety symptoms is defined 
by SAS scores >44 (48). The State Trait 
Anxiety Index Y2 (STAI-Y2) is one of 
the most widely used instruments for 
measuring trait anxiety. STAI-Y2 is a 
40-item scale which evaluates relative-
ly stable aspects of anxiety proneness, 
including general states of calmness, 
confidence, and security. Item scores 
are added to obtain a possible range 
of scores of 20–80, higher scores indi-
cating greater anxiety (49). Both have 
been used in SLE cohorts (41, 50, 51). 
Conclusion
NP assessment in SLE is a continuous 
challenge both for clinical and research 
purposes.
This review highlights how the use of 
a standardised clinical interview by 
questionnaires is important in recognis-
ing neuropsychiatric symptoms in SLE 
patients. These, even if subtle and mild, 
could otherwise be overlooked during 
routine clinical assessment.
Indeed, physician and patient-adminis-
tered questionnaires represent a funda-
mental tool to standardise evaluation, 
early detection of symptoms and quan-
tification of the severity and progress of 
a particular manifestation. 
So far, few instruments have been 
developed to specifically asses NP 
symptoms in SLE. The limits of these 
instruments are that they have not yet 
been validated in larger and independ-
ent SLE cohorts and that they can de-
pict NP symptoms but their ability in 
symptoms attribution to SLE or to other 
Table I. Tests used to assess cognitive impairment in SLE.
Patients Test used to asses CI in SLE Feasibility 
Author, year  -1. time required  
Study design;  -2. comprehensibility 
Number of patients   -3. Special technology
  -4. Costs
Carlomagno S, 2000 MDB -1: 1 hour 
LOS (Mental Deterioration Battery) -2 :expert psychometrist
51  -3 : no
  -4: N.A.
Alarcòn GS, 2002 CSI -1: 10 minutes
Cross-sectional (Cognitive Symptoms Inventory) -2 self administered with
156  limited assistance 
  -3 No
  -4 N.A.
Denburg SD, 2003 42-ITEMS, -1 N.A. 
LOS 25-ITEMS, -2 self administered
30 8- ITEMS -3: NA
 NP-questionnaire -4 N.A.
Holliday SL, 2003 ANAM -1 N.A.
Cross-sectional (Automated Neuropsychological -2  N.A
67 Assessment Metrics ) -3 Personal Computer
  -4 N.A.
Shucard JL, 2004 PASAT -1  N.A.
Cross-sectional (Paced Auditory Serial Addition -2 :Yes
45 Test): processing speed and -3 Audiotape 
 working memory -4 N.A.
Kozora E,2004 ACR neuropsychological battery 1.1 hour




Roebuck-Spencer TM, 2006 ANAM 1.30 minutes
Cross-sectional (Automated Neuropsychological 2.self administered
60  Assessment Metrics) 3.Personal computer
  4.NA
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causes remains to be clarified. On the 
other hand, many instruments validated 
for the general population have been 
also applied to SLE patients but the 
reliability of these measures in such a 
specific population remains to be evalu-
ated. Indeed, it is well known that the 
population in which a questionnaire has 
been validated may be different from 
our study population, and prudence 
must be used in interpreting the data.
There is therefore a clear case for vali-
dation studies in this area and their 
wider implementation is still warrant-
ed. The broader use of such instruments 
could have important consequences; 
first of all, by standardising symptom 
assessment, a better definition of the 
prevalence of NP manifestation across 
different centres could be achieved. 
Secondly, prospective studies could 
allow for the evaluation of clinical 
significance of mild symptoms and 
their impact on the patient’s function 
and quality of life. Indeed, literature 
data suggest that the assessment of NP 
symptoms by structured questionnaires, 
especially if self-administered, is able 
to pick up subjective and shadowy 
complaints that significantly contrib-
ute to the disease burden, irrespectively 
of clinical attribution; however, these 
symptoms are usually neglected by the 
physician-driven routine assessment. 
By including the patient’s perspective, 
a more exhaustive estimation of the NP 
picture could be accomplished, with 
important therapeutic and prognostic 
consequences. 
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